Takeda Submits New Drug Application for Extended-Release Type 2 Diabetes Medication, ACTOSplus met(tm) (pioglitazone HCl and metformin HCl)
New Data Shows Takeda’s ACTOS® (pioglitazone HCl) Reduced Heart Attacks By 28 Percent in People with Type 2 Diabetes
PROactive Study Shows Takeda’s ACTOS® (pioglitazone HCl) Reduced Heart Attacks, Strokes and Deaths in Patients with Type 2 Diabetes
